ECO Animal Health shares surge on poultry drug milestone
The share price of ECO Animal Health Group Plc surged on Monday after European regulators recommended marketing authorisation for its poultry vaccine ECOVAXXIN MS.
The AIM-listed company, which focuses on treatments for respiratory and enteric diseases in pigs and poultry, said the key milestone now establishes a roadmap for the commercial launch of the drug in the second half of 2026.
ECOVAXXIN MS is an immunisation against mycoplasma synoviae, which can cause air-sac and foot-pad lesions in poultry, which can result in a 5-10% reduction in the number of eggs laid by affected hens.
David Hallas, chief executive of ECO Animal Health, said he was "delighted" by the announcement from the the Committee for Medicinal Products for Veterinary Use of the European Medicines Agency.
"This marks an exciting time for the company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO's next phase of growth."
The stock was up 8.4% at 87.8p by 1136 GMT.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
